These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 33145728)

  • 21. Mesenchymal-like immune-altered is the fourth robust triple-negative breast cancer molecular subtype.
    Jézéquel P; Lasla H; Gouraud W; Basseville A; Michel B; Frenel JS; Juin PP; Ben Azzouz F; Campone M
    Breast Cancer; 2024 Sep; 31(5):825-840. PubMed ID: 38777987
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field.
    Yam C; Mani SA; Moulder SL
    Oncologist; 2017 Sep; 22(9):1086-1093. PubMed ID: 28559413
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo.
    Barton VN; D'Amato NC; Gordon MA; Lind HT; Spoelstra NS; Babbs BL; Heinz RE; Elias A; Jedlicka P; Jacobsen BM; Richer JK
    Mol Cancer Ther; 2015 Mar; 14(3):769-78. PubMed ID: 25713333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting triple-negative breast cancer: A clinical perspective.
    Popovic LS; Matovina-Brko G; Popovic M; Punie K; Cvetanovic A; Lambertini M
    Oncol Res; 2023; 31(3):221-238. PubMed ID: 37305385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spectrum of PIK3CA/AKT mutations across molecular subtypes of triple-negative breast cancer.
    Kumar S; Bal A; Das A; Loriya I; Khare S; Bhattacharya S; Singh G
    Breast Cancer Res Treat; 2021 Jun; 187(3):625-633. PubMed ID: 33954864
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Machine Learning Approach to Differentiate Two Specific Breast Cancer Subtypes Using Androgen Receptor Pathway Genes.
    Hu T; Zhao G; Liu Y; Long M
    Technol Cancer Res Treat; 2021; 20():15330338211027900. PubMed ID: 34159849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?
    Le Du F; Eckhardt BL; Lim B; Litton JK; Moulder S; Meric-Bernstam F; Gonzalez-Angulo AM; Ueno NT
    Oncotarget; 2015 May; 6(15):12890-908. PubMed ID: 25973541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Luminal androgen receptor (LAR) subtype of triple-negative breast cancer: molecular, morphological, and clinical features.
    Vtorushin S; Dulesova A; Krakhmal N
    J Zhejiang Univ Sci B; 2022 Aug; 23(8):617-624. PubMed ID: 35953756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance.
    Hill DP; Harper A; Malcolm J; McAndrews MS; Mockus SM; Patterson SE; Reynolds T; Baker EJ; Bult CJ; Chesler EJ; Blake JA
    BMC Cancer; 2019 Nov; 19(1):1039. PubMed ID: 31684899
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular Subtyping of Triple Negative Breast Cancer by Surrogate Immunohistochemistry Markers.
    Kumar S; Bal A; Das A; Bhattacharyya S; Laroiya I; Khare S; Singh G
    Appl Immunohistochem Mol Morphol; 2021 Apr; 29(4):251-257. PubMed ID: 33337632
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imaging features of triple-negative breast cancers according to androgen receptor status.
    Candelaria RP; Adrada BE; Wei W; Thompson AM; Santiago L; Lane DL; Huang ML; Arribas EM; Rauch GM; Symmans WF; Gilcrease MZ; Huo L; Lim B; Ueno NT; Moulder SL; Yang WT
    Eur J Radiol; 2019 May; 114():167-174. PubMed ID: 31005169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrative analysis of breast cancer profiles in TCGA by TNBC subgrouping reveals novel microRNA-specific clusters, including miR-17-92a, distinguishing basal-like 1 and basal-like 2 TNBC subtypes.
    Kalecky K; Modisette R; Pena S; Cho YR; Taube J
    BMC Cancer; 2020 Feb; 20(1):141. PubMed ID: 32085745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
    Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
    BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathogenesis of Triple-Negative Breast Cancer.
    Derakhshan F; Reis-Filho JS
    Annu Rev Pathol; 2022 Jan; 17():181-204. PubMed ID: 35073169
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes.
    Basho RK; Zhao L; White JB; Huo L; Bassett RL; Mittendorf EA; Thompson A; Litton JK; Ueno N; Arun B; Lim B; Valero V; Tripathy D; Zhang J; Adrada BE; Santiago L; Ravenberg E; Seth S; Yam C; Moulder SL; Damodaran S
    JCO Precis Oncol; 2024 Mar; 8():e2300124. PubMed ID: 38484209
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.
    Jézéquel P; Loussouarn D; Guérin-Charbonnel C; Campion L; Vanier A; Gouraud W; Lasla H; Guette C; Valo I; Verrièle V; Campone M
    Breast Cancer Res; 2015 Mar; 17():43. PubMed ID: 25887482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping.
    Hartung C; Porsch M; Stückrath K; Kaufhold S; Staege MS; Hanf V; Lantzsch T; Uleer C; Peschel S; John J; Pöhler M; Weigert E; Buchmann J; Bürrig KF; Schüler K; Bethmann D; Große I; Kantelhardt EJ; Thomssen C; Vetter M
    Breast Care (Basel); 2021 Dec; 16(6):637-647. PubMed ID: 35082572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determination of target genes for classified molecular subtypes of triple-negative breast cancer form microarray gene expression profiling: An integrative in silico approach.
    Ray M; Banik S; Sable MN
    Indian J Pathol Microbiol; 2024 Jul; 67(3):533-541. PubMed ID: 38718221
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Translating the molecular message of triple-negative breast cancer into targeted therapy.
    Vidula N; Rugo HS
    Clin Cancer Res; 2015 Apr; 21(7):1511-3. PubMed ID: 25351747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
    Barton VN; D'Amato NC; Gordon MA; Christenson JL; Elias A; Richer JK
    Horm Cancer; 2015 Dec; 6(5-6):206-13. PubMed ID: 26201402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.